NaviFUS and Bracco cooperation model in the works
NaviFUS and Bracco have recently made great progress towards an early-stage cooperation agreement that is expected to be finalized in the near future. Bracco’s microbubble products will be used together with NaviFUS’ NaviFUS system, which uses focused ultrasound to stimulate microbubbles to temporarily open the Blood-Brain-Barrier (BBB) and allow enhanced drug delivery.
Bracco will provide the microbubble products, while NaviFUS will be responsible for future clinical trials, regulatory submissions, and commercialization. The two companies have agreed on future pricing and royalties for the microbubble supply, and the formal agreement is expected to be completed in the next three months.
Dr. Arthur Lung, CEO of NaviFUS, said “The partnership is a milestone in the company’s product commercialization. In addition to confirming the regulatory classification of the product, the formal business agreement will allow Bracco’s microbubbles to be sold as consumables for the NaviFUS system, which will help contribute to the company’s future revenue.
NaviFUS expects that Bracco’s microbubble products will be used in its upcoming recurrent brain tumor (rGBM) pivotal trial, and once they have obtained the marketing approval for rGBM treatment, Bracco will be responsible for microbubble supply, while NaviFUS will be responsible for device supply and sales of consumables.
About NaviFUS
NaviFUS is a Taiwan medical device company specializing in non-invasive, precise, and cost-effective focused ultrasound (FUS) solutions for clinically unmet needs. Many brain-related diseases currently lack effective drug treatments, as drug delivery to the brain remains a major hurdle to translational therapy. NaviFUS aims to drive revolutionary clinical solutions for patients through FUS interventions while also providing value to pharmaceutical companies by potentially enhancing drug efficacy
About Bracco Imaging
Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions. It offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Bracco Imaging’s continually evolving portfolio is completed by a range of medical devices, advanced administration systems and dose-management software.